LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Akciju saraksts・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Slēgts

4.05 -0.98

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.03

Max

4.05

Galvenie mērījumi
By Trading Economics
Ienākumi	-136K -35M
Darbinieki	106
EBITDA	-619K -38M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+72.41% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-36M 258M
Iepriekšējā atvēršanas cena	5.03
Iepriekšējā slēgšanas cena	4.05

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. maijs 23:46 UTC

Tirgus saruna

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

2026. g. 24. maijs 23:45 UTC

Tirgus saruna

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

2026. g. 24. maijs 23:42 UTC

Tirgus saruna

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

2026. g. 24. maijs 23:34 UTC

Tirgus saruna

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

2026. g. 24. maijs 23:11 UTC

Tirgus saruna

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

2026. g. 24. maijs 22:26 UTC

Iegādes, apvienošanās, pārņemšana

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

2026. g. 24. maijs 22:25 UTC

Iegādes, apvienošanās, pārņemšana

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

2026. g. 24. maijs 22:25 UTC

Iegādes, apvienošanās, pārņemšana

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

2026. g. 24. maijs 22:24 UTC

Iegādes, apvienošanās, pārņemšana

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

2026. g. 24. maijs 22:24 UTC

Iegādes, apvienošanās, pārņemšana

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

2026. g. 24. maijs 22:23 UTC

Iegādes, apvienošanās, pārņemšana

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

2026. g. 24. maijs 22:23 UTC

Iegādes, apvienošanās, pārņemšana

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

2026. g. 24. maijs 22:11 UTC

Tirgus saruna

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

2026. g. 24. maijs 22:04 UTC

Tirgus saruna

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

2026. g. 23. maijs 08:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 23. maijs 08:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 22. maijs 21:10 UTC

Peļņas

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

2026. g. 22. maijs 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 22. maijs 20:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 22. maijs 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 22. maijs 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 22. maijs 19:47 UTC

Peļņas

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

2026. g. 22. maijs 19:17 UTC

Tirgus saruna

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

2026. g. 22. maijs 19:10 UTC

Tirgus saruna

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

2026. g. 22. maijs 18:54 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 22. maijs 18:54 UTC

Tirgus saruna

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

2026. g. 22. maijs 18:38 UTC

Tirgus saruna

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

2026. g. 22. maijs 18:35 UTC

Iegādes, apvienošanās, pārņemšana

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

2026. g. 22. maijs 18:09 UTC

Tirgus saruna

Centralized Crypto Lending Slows in 1Q -- Market Talk

2026. g. 22. maijs 17:58 UTC

Tirgus saruna

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

72.41% augšup

Prognoze 12 mēnešiem

Vidējais 7 USD 72.41%

Augstākais 10 USD

Zemākais 4 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

7 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 7 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.